Sep 22, 2026
Celldex barzolvolimab Phase 3 trials meet endpoints but report two anaphylaxis cases
Celldex Therapeutics' barzolvolimab achieved what analysts called best-in-class efficacy results in two Phase 3 trials for chronic spontaneous urticaria, meeting all primary and key secondary endpoints. However, the trials also reported two life-threatening anaphylaxis cases, causing shares to drop 13-15% despite the positive efficacy data.
6 sources
00